Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results